Biokinetics of 18F-choline studied in four prostate cancer patients.

Biokinetic data are important when calculating the absorbed dose to the patients and can also be used to find the optimal time between injection and imaging. To the authors' knowledge, there are no published biokinetic data in humans for (18)F-choline, except some distribution data at single time points. Four patients with suspicion of metastases due to biochemical recurrence (measurable prostate-specific antigen in plasma) after radical prostatectomy were injected with (18)F-choline. Four whole-body PET/CT images were taken with 1 h interval, starting immediately after injection. Blood samples were taken and all urine was collected for 3.5 h. The corrected decay activity content in the kidneys was 22-37 % higher immediately after injection when compared with the later time points. The highest activity concentration was found in kidneys (43 kBq ml(-1)). The organ with highest activity content was the liver (11 % of injected activity, % IA). Thirty minutes after the injection 4-16 % IA was left in the blood. Less than 9 % IA was excreted with the urine during the first 3.5 h after injection.

[1]  T. Hara.  11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[2]  J. Pruim,et al.  Visualization of prostate cancer with 11C-choline positron emission tomography. , 2002, European urology.

[3]  Sven N. Reske,et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma , 2000, European Journal of Nuclear Medicine.

[4]  N. Avril,et al.  Molecular positron emission tomography and PET/CT imaging in urological malignancies. , 2007, European urology.

[5]  S. Nadler,et al.  Prediction of blood volume in normal human adults. , 1962, Surgery.

[6]  Robert A. Harris,et al.  Biodisposition and metabolism of [18F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Takako Yamaguchi,et al.  Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  R. Coleman,et al.  Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  A. Pupi,et al.  Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer , 2008, La radiologia medica.

[10]  T. Block,et al.  Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy , 1999, European Urology.

[11]  M. Terris,et al.  Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. , 2001, Urology.

[12]  Reiman,et al.  9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[13]  A. Dirisamer,et al.  Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml? , 2005, Molecular Imaging and Biology.

[14]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Heiko Schöder,et al.  Positron emission tomography for prostate, bladder, and renal cancer. , 2004, Seminars in nuclear medicine.

[16]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.

[17]  R. Coleman,et al.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. , 2001, Cancer research.

[18]  R. Coleman,et al.  Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. , 2002, The Journal of urology.

[19]  R. Coleman,et al.  Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.